Examining the Use of Checkpoint Inhibitors in Bladder Cancer
Thursday, December 5, 2019
Renaissance Capital Ballroom
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia School of Medicine
Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Cancer Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine in Charlottesville, Virginia. Dr. Dreicer previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center in Cleveland, Ohio. He is Board Certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies, and the design and conduct of clinical trials in urologic oncology.
Dr. Dreicer received his BS Degree at Colorado State University and his MS Degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his Medical Degree from the University of Texas Medical School in Houston, Texas. He completed an Internal Medicine residency at Indiana University in Indianapolis, Indiana, followed by a Medical Oncology Fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology and served as Principal Investigator in a large number of studies in genitourinary neoplasms. He previously served as Co-Chair of the National Cancer Institute Genitourinary Cancers Steering Committee and is a member of the editorial board of the New England Journal of Medicine’s Journal Watch Hematology and Oncology. In October 2016, he was awarded Mastership in the American College of Physicians.
Ashish Kamat, MD, MBBS, FACS
University of Texas, MD Anderson Cancer Center
Dr. Kamat is a Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. He is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on developing novel therapies, and identifying predictors of response to therapy (eg, intravesical immunotherapy), as a first step toward personalized cancer therapeutics. He has initiated, led, and been active in several large studies, including multinational trials in bladder cancer with findings published in high-impact journals.
Dr. Kamat is listed in ‘Who’s Who in Medicine’ and ‘Best Doctors in America’ and has won the ‘Compassionate Doctor Award’ from patient groups. He is President of the International Bladder Cancer Group and President of the International Bladder Cancer Network. He is also Associate Editor, European Urology Oncology and Associate Cancer Center Director, RFHNH, Mumbai, India.
Neal Shore, MD, FACS
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Dr. Shore is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. Dr. Shore serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee, and currently is a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank. He is on the editorial boards of Urology Times,Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology. Dr. Shore has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology, Journal Urology, Urology, BJU International, Prostate Cancer and Prostatic Diseases, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a six-month Clinical Research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York-Presbyterian/Weill Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York, New York. He is a Fellow of the American College of Surgeons.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE request form, statements of credit for physicians will be issued via email within 30 business days.